news
Sanofi to enhance neurology pipeline with new acquisition
The acquisition aligns with one of Sanofi’s four strategic disease areas and supports the company in utilising its immunology expertise to address areas of unmet need.
List view / Grid view
R&D
article
Measuring AI’s impact on the pharmaceutical industry
In this article, Updesh Dosanjh, Practice Leader, Pharmacovigilance Technology Solutions, IQVIA, explores how the pharmaceutical industry and its workforce can truly leverage the potential of artificial intelligence (AI) and measure the impact of this technology.
news
BioNTech pledges major UK investment
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
news
New real-world data guidance could accelerate drug approvals
The MHRA’s consultation, announced on International Clinical Trials Day, is intended to support creation of innovative UK trials.
news
UK Government commits to long-term R&D funding
The announcement supports the UK Government’s broader plans for reformation of longer-term funding for the research and development sector.
article
Pharma Horizons: the future of cell and gene therapy
This exclusive report addresses the key challenges and breakthroughs shaping the future of cell and gene therapy, from QC and analytical development to advanced manufacturing strategies. Discover practical solutions you can implement to drive progress for your organisation.
article
UK immigration reform – implications for life sciences
This article offers key industry perspectives on the UK government’s recent immigration whitepaper and highlights the challenge of balancing economic growth and attracting skilled talent.
news
Takeda investigational drug shows efficacy in narcolepsy
If approved, the oral medicine could provide a first-in-class treatment option for eligible individuals with the chronic 24-hour disease.
news
GSK to expand hepatology pipeline with potential best-in-class therapy
The unique mechanism of action of efimosfermin supports its potential as a new standard-of-care in liver disease.
news
World-first approval supports AstraZeneca’s sustainability goals
Approval of the novel tool marks progress for both respiratory disease patients in the UK and reducing the global environmental impact of inhaled medicines.
news
Innovative CAR T therapy could deliver in broader therapeutic settings, research suggests
The novel cell therapy utilises a shortened manufacturing process compared to standard production timelines, offering potential for enhanced therapeutic capability.
article
Qualification of non-mutagenic impurities (NMIs)
In this article, Dave Elder reviews the European Medicines Agency (EMA)’s updated reflection paper on the qualification of non-mutagenic impurities (NMIs), which outlines alternative approaches to animal testing.
news
Improving EU’s regulatory framework for enhanced pharma competitiveness
Despite its potential to become a more attractive destination for drug developers, new research insists the EU market makes improvements such as faster regulatory approvals and closer collaboration.
news
New J&J data signals progress in ulcerative colitis treatment landscape
The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show.
news
FDA approves first-of-a-kind gene therapy for dystrophic epidermolysis bullosa
With clinical data showing the gene therapy can address large and challenging chronic wounds, the FDA’s decision will help improve quality of life for dystrophic epidermolysis bullosa (DEB) patients.
